Time filter

Source Type

Ince D.,Dokuz Eylül University | Demirag B.,Pediatric Hematology Oncology Clinic | Ozek G.,Pediatric Hematology Oncology Clinic | Erbay A.,Baskent University | And 6 more authors.
Turkish Journal of Pediatrics | Year: 2016

This study aimed to analyze children with the diagnosis of Langerhans cell histiocytosis (LCH) who were diagnosed and treated between 1998–2015. Medical records were evaluated retrospectively for clinical and laboratory features, treatment details, and outcome. There were 20 patients, the median age of diagnosis was 37 months, M/F ratio: 1.5. Nine had single system (SS), 11 had multisystem (MS) LCH. Spontaneous regression occurred in three infants with skin limited LCH. Eight patients had risk organ involvement in MS-LCH group. The curettage alone was performed in only one case. Patients received LCH-II/ LCH-III based chemotherapy schema. Radiotherapy was performed to vertebral disease and residual craniofacial bone disease in four cases. The regression and relapse rates were 100% and 33% for SS-LCH. The regression and relapse rates were 73%, and 18% for MS-LCH. Two infants with MS-LCH died despite chemotherapy. Pulmonary and liver involvements affected outcome adversely in MS-LCH. Multidisciplinary treatment approaches are needed. © 2016, Turkish Journal of Pediatrics. All rights reserved.

Loading Pediatric Hematology Oncology Clinic collaborators
Loading Pediatric Hematology Oncology Clinic collaborators